ProPhase Labs, Inc. (NASDAQ:PRPH) issued its quarterly earnings results on Monday. The company reported ($0.05) earnings per share for the quarter, Bloomberg Earnings reports. ProPhase Labs had a return on equity of 54.87% and a net margin of 270.98%.

ProPhase Labs (NASDAQ PRPH) remained flat at $$2.25 during mid-day trading on Tuesday. The company’s stock had a trading volume of 44,400 shares, compared to its average volume of 22,938. ProPhase Labs has a 1 year low of $1.78 and a 1 year high of $2.45. The company has a market cap of $36.38, a price-to-earnings ratio of 2.71 and a beta of 0.15.

ProPhase Labs announced that its board has approved a stock buyback program on Tuesday, August 15th that permits the company to repurchase 4,000,000 shares. This repurchase authorization permits the company to buy shares of its stock through a tender offer. Stock repurchase programs are often a sign that the company’s board believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “ProPhase Labs, Inc. (PRPH) Announces Earnings Results” was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this story on another domain, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The legal version of this story can be accessed at

Separately, ValuEngine cut shares of ProPhase Labs from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th.

In other news, major shareholder Braden Michael Leonard sold 1,695,305 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $2.30, for a total value of $3,899,201.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Ted William Karkus sold 364,950 shares of the firm’s stock in a transaction on Friday, September 29th. The stock was sold at an average price of $2.30, for a total transaction of $839,385.00. Following the completion of the sale, the chief executive officer now owns 2,309,638 shares of the company’s stock, valued at approximately $5,312,167.40. The disclosure for this sale can be found here. Insiders sold a total of 2,423,255 shares of company stock valued at $5,573,487 in the last 90 days. Company insiders own 29.60% of the company’s stock.

About ProPhase Labs

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Earnings History for ProPhase Labs (NASDAQ:PRPH)

Receive News & Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related companies with's FREE daily email newsletter.